Zai Lab pulled back after the biopharmaceutical reported fourth-quarter results. The biotech is building a cup base.
The Harding Loevner Emerging Market Equity composite fell 8.1% (gross) during Q4 2024, wider than the 7.8% loss of the MSCI Emerging Markets Index. Click here to read more.